Id2-Dependent Anti-Tumor Immunity Promotes Anti-Cancer Therapies Effects

Xiaohuan Guo

DOI: https://doi.org/10.4049/jimmunol.198.supp.126.7

2017-01-01

Abstract:Abstract More and more studies show that the efficacy of many kinds of anti-cancer therapies, including chemotherapy, radiotherapy, targeting therapy and even immunotherapy, require host activated anti-tumor immune responses. However, the regulation mechanisms of anti-tumor immunity are not fully understood yet. Here, we show that a transcription regulator, Inhibitor of DNA binding 2 (ID2), could positively regulate the anti-tumor immunity. E and ID proteins are both HLH proteins and play important roles in the development of various immune cells. E proteins can form homodimers or heterodimers with HLH proteins and function as transcription activators or repressors, while ID proteins can prevent E proteins from binding to DNA. With a T cell specific ID2 knockout mice (Cd4-cre; Id2 fl/fl), we found that the anti-cancer efficacy of oxaliplatin and anti-PD-L1 treatment for subcutaneous transplant tumor model required ID2 expression in T cells. Further experiments showed that these anti-cancer therapies could induce IFNg production in wild type mice, but failed in ID2 deficient mice. Moreover, the tumor infiltrating cytotoxic CD8+ T cells, but not CD4+ T cells, were dramatically reduced in ID2 deficient mice compared their littermate controls. Our hypothesis is that post the anti-cancer therapy, ID2 could be upregulated and promote CD8+ T cell activation and migration into the tumor sites, then mediate the anti-tumor effect. Since E proteins are main targets of ID2, small molecules targeting E protein may be new choices for boosting anti-tumor immunity to enhance the efficacy of anti-cancer therapies. Supported by grants from Tsinghua University and The Recruitment Program for Young Professionals (to X.G.).